# Eurofarma

> Eurofarma is a VC fund in São Paulo backing Therapeutics and Biotechnology. See 4 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: São Paulo, Brazil
- Total investments: 4
- Last investment: Dec 2025
- Lead investor: 50%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/eurofarma/
- Website: https://www.eurofarma.com.br/en/
- Facebook: https://www.facebook.com/eurofarma

Eurofarma is a VC fund in São Paulo focused on Therapeutics and Biotechnology. Eurofarma is the first Brazilian multinational pharmaceutical company, founded in 1972, present in Latin America. It operates in all major pharmaceutical segments, occupying the 2nd position in the most prescribed laboratories ranking by the Brazilian medical community and is among the Top 4 generic drug laboratories in the country. Holder of abroad range of products, it also holds licenses and strategic partnerships for the promotion and marketing of third party’s products. The company's sales added up to around US$ 1 billion in 2014, reaching a 20% growth over the previous year. Licenses accounted for 10% of the total, approximately. Eurofarma has the largest medical sales force in Brazil (about 2,000 representatives) and is considered one of the best companies to work for, according to key publications. The company keeps its own operations in 15 countries, has over 10 manufacturing plants strategically located and an ambitious internationalization plan with growing investment in the R&D area.

## Contacts

5 contacts available for Eurofarma. Shizune tracks 1 team members at Eurofarma. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/eurofarma?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Therapeutics | 3 | 75% |
| Biotechnology | 3 | 75% |
| Health Care | 2 | 50% |
| Retail | 1 | 25% |
| Medical | 1 | 25% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 1 | 25% |
| Series B | 1 | 25% |
| Corporate Round | 1 | 25% |
| Post-IPO Equity | 1 | 25% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 2 | 50% |
| Brazil | 1 | 25% |
| United Kingdom | 1 | 25% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Galliano Billi | Founder | 0 | https://shizune.co/investors/profile/galliano-billi |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Psivant Therapeutics | Psivant Therapeutics is a biotechnology company that offers drug design, biology research, and development services. | $47.5M | Series A | Dec 10, 2025 |  |
| Abcuro | Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both autoimmunity and cancer. They leverage the systematic target validation and clinical insights gained by its founders to identify new targets. Their intensive use of bioinformatics to interrogate the transcriptome of human disease together with ex-vivovalidation in diseased tissue has uncovered new approaches to target key compartments of the immune system.The company was incorporated in 2015 and is based in Newton, Massachusetts. | $155M | Series B | Aug 17, 2023 |  |
| JustForYou | JustForYou provides hair solutions. Their product includes cleaning, hydration, and finalization, treatment, finalization, hydration, and antifrizz. They analyze and create the formulation for the hair . |  | Corporate Round | Mar 17, 2022 |  |
| Summit Therapeutics | Summit Therapeutics is a clinical-stage drug discovery and development company. The company's new mechanism antibiotics are designed to become the new standards of care for the benefit of patients and create value for payors and healthcare providers. | $1M | Post-IPO Equity | Feb 06, 2020 |  |

4 of 4 investments shown.

## Co-investors
- [Samsara BioCapital](https://shizune.co/investors/profile/samsara-biocapital) — VC Fund, 2 deals together
- [Bain Capital Life Sciences](https://shizune.co/investors/profile/bain-capital-life-sciences) — VC Fund, 1 deal together
- [BlackRock](https://shizune.co/investors/profile/blackrock) — VC Fund, 1 deal together
- [Lightstone Ventures](https://shizune.co/investors/profile/lightstone-ventures) — VC Fund, 1 deal together
- [Mass General Brigham Ventures](https://shizune.co/investors/profile/mass-general-brigham-ventures) — VC Fund, 1 deal together
- [New Leaf Ventures](https://shizune.co/investors/profile/new-leaf-ventures) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Eurofarma invest in?

Eurofarma invests primarily in Therapeutics, Biotechnology and Health Care startups, most often at Series A and Series B stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Eurofarma?

Public channels for Eurofarma include LinkedIn, the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Eurofarma?

The team at Eurofarma includes Galliano Billi (Founder). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co